8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps; Thomas Vanwolleghem; Marc van der Valk; Guido E van den Berk; Marjo van Kasteren; Dirk Posthouwer; Anthonius S M Dofferhoff; Bart van Hoek; Dewkoemar Ramsoekh; Jelle Koopsen; Janke Schinkel; Eric Florence; Joop E Arends; Bart J Rijnders

doi:10.1016/j.jhep.2018.10.032

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

J Hepatol. 2019 Mar;70(3):554-557. doi: 10.1016/j.jhep.2018.10.032. Epub 2018 Dec 5.

Authors

Affiliations

¹ Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands.
² Department of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp, Belgium; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
³ Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Academic Medical Center, Amsterdam, the Netherlands.
⁴ Department of Internal Medicine and Infectious Diseases, OLVG, Amsterdam, the Netherlands.
⁵ Department of Internal Medicine and Infectious Diseases, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands.
⁶ Department of Internal Medicine and Medical Microbiology, Maastricht Universitair Medisch Centrum+, Maastricht, the Netherlands.
⁷ Department of Internal Medicine and Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
⁸ Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
⁹ Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands.
¹⁰ Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, the Netherlands.
¹¹ Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
¹² Department of Internal Medicine and Infectious Diseases, Universitair Medisch Centrum Utrecht, Utrecht University, Utrecht, the Netherlands.
¹³ Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands. Electronic address: bartrijnders@me.com.

PMID: 30527953
DOI: 10.1016/j.jhep.2018.10.032

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / administration & dosage
Benzimidazoles / administration & dosage*
Drug Monitoring / methods*
Duration of Therapy*
Female
Fluorenes / administration & dosage*
Hepacivirus* / genetics
Hepacivirus* / isolation & purification
Hepatitis C, Chronic* / drug therapy
Hepatitis C, Chronic* / epidemiology
Hepatitis C, Chronic* / virology
Humans
Male
Middle Aged
Netherlands / epidemiology
Outcome Assessment, Health Care
RNA, Viral / analysis*
Sofosbuvir
Sustained Virologic Response
Uridine Monophosphate / administration & dosage
Uridine Monophosphate / analogs & derivatives*

Substances

Antiviral Agents
Benzimidazoles
Fluorenes
RNA, Viral
ledipasvir, sofosbuvir drug combination
Uridine Monophosphate
Sofosbuvir